Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
The hepatitis C virus (HCV) genotype influences efficacy of interferon (IFN)-based therapy. HCV protease inhibitors are being licensed for treatment of genotype 1 infection. Because there are limited or no data on efficacy against HCV genotypes 2-7, we aimed at developing recombinant infectious cell culture systems expressing genotype-specific nonstructural (NS) protein 3 protease (NS3P).
Originalsprog | Engelsk |
---|---|
Tidsskrift | Gastroenterology Today |
Vol/bind | 141 |
Udgave nummer | 3 |
Sider (fra-til) | 1067-1079 |
Antal sider | 13 |
ISSN | 0969-0131 |
DOI | |
Status | Udgivet - 2011 |
ID: 40329614